**
In a troubling revelation, internal records have unveiled that top officials from the Trump administration’s Environmental Protection Agency (EPA) engaged in discussions with Bayer’s CEO, Bill Anderson, regarding the company’s ongoing legal battles related to its glyphosate herbicides. This meeting, which took place on June 17, 2025, is emblematic of a larger pattern where corporate interests appear to hold sway over public health concerns, particularly as thousands of individuals allege that these products have caused cancer.
High-Level Meeting Uncovered
The meeting between Bayer’s executives and EPA officials came at a critical time for the German-based corporation, which has faced a barrage of lawsuits from individuals claiming that their health has been compromised due to exposure to glyphosate-based products like Roundup. With litigation costs soaring into the billions, Bayer’s strategy has hinged on persuading the Supreme Court to dismiss these claims by arguing that if the EPA does not mandate a cancer warning for glyphosate, the company cannot be held accountable for failing to provide such warnings.
Documents obtained through a Freedom of Information Act request indicate that the discussions included “litigation” and “supreme court action,” raising red flags about the nature of the conversations between private corporate interests and public regulators. The agenda for the meeting, as outlined in an internal EPA email, included an update on Bayer’s legal standing and potential labelling options, signalling an apparent alignment of interests between the agency and a major pesticide manufacturer.
Political Support for Bayer
Following the June meeting, the Trump administration exhibited a series of actions that bolstered Bayer’s position in court. In a formal brief submitted to the Supreme Court on December 1, 2025, the solicitor general appointed by Trump urged the court to hear Bayer’s case, which it subsequently agreed to do, setting a hearing date for April 27, 2026. Additionally, the White House invoked the Defense Production Act in February 2026 to secure the production of glyphosate herbicides, effectively shielding Bayer from the consequences of potential legal liabilities.
These actions have drawn sharp criticism from environmental advocates and legal experts alike. Nathan Donley, environmental health science director for the Center for Biological Diversity, expressed alarm at the evident prioritisation of corporate profits over public health, stating, “When the CEO of one of the largest companies in the world is meeting with political appointees in a US regulatory office, it shows just how much power and influence these corporations have on decisions that can have very real consequences for the health of all Americans.”
Community Voices Silenced
The implications of these meetings extend beyond corporate legal battles; they raise fundamental questions about the transparency and fairness of regulatory processes that should prioritise public health. Critics have pointed out the stark contrast between the access afforded to powerful corporate leaders and the lack of opportunity for everyday citizens affected by Bayer’s products to voice their concerns.
Whitney Di Bona, a consumer safety advocate, highlighted this imbalance: “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability. We should also ask whether the agency gave the same chance to speak to the thousands of people who say they got cancer after using Roundup.”
Moreover, Zen Honeycutt, founder of Moms Across America, echoed these sentiments, emphasising that community organisations have struggled for meaningful dialogue with the EPA. “Coercion by chemical companies on our regulatory agencies is nothing new,” she remarked, underscoring the longstanding tension between corporate lobbying and grassroots advocacy.
Why it Matters
The revelation of these meetings raises urgent questions about the integrity of regulatory processes and the extent to which corporate interests may overshadow public health priorities. As Bayer continues to battle lawsuits over its glyphosate products, the apparent collusion between the company and government officials sends a clear message: the health of countless Americans could be jeopardised in the name of profit. This situation highlights the critical need for greater transparency and accountability in environmental regulations, ensuring that the voices of those impacted by corporate malfeasance are heard and valued in the policy-making process. As the fight against glyphosate continues, the stakes have never been higher for public health advocacy and environmental justice.
